Heavier FTC Scrutiny Puts Pressure On Consumer Health Product Claims
This article was originally published in The Tan Sheet
Executive Summary
Attorneys say marketers should make structure/function claims with knowledge that no claims are safe from FTC scrutiny. During the Food & Drug Law Institute annual meeting, stakeholders commented on how FTC’s stance on Bayer Health Care’s Philips Colon Health will impact other claims.
You may also be interested in...
FTC Requests Drug Claim Support For Bayer Probiotic Supplement
On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.
US FDA Cosmetics Director Lists Talc, Formaldehyde In Hair Smoothers Among Priorities
Linda Katz, director of the FDA’s Office of Cosmetics and Colors, touched on cosmetics modernization legislation in her 21 September presentation on agency priorities at the Independent Beauty Association’s virtual FDA Cosmetics Regulations Workshop.
PFAS Remain High Priority For US FDA’s Cosmetics Office – Director Linda Katz
“We’ve been keeping tabs of the amount of products containing PFAS over the last several years and, unfortunately, we’re not seeing really a lot of it going away,” said Katz, director of the Office of Cosmetics and Colors, at the Independent Beauty Association’s Cosmetics Regulations Workshop.